Multispecific Platform Advantage Leverage ModeX’s multispecific platform to attract licensing or co development deals for access to single molecule multispecific antibodies and vaccines. The broad target coverage in solid and liquid tumors as well as viral threats positions the company to partner with oncology and infectious disease players seeking modality diversification. Ideal partners include mid to large cap pharma and biotech firms looking to accelerate therapeutic development, with options for platform licensing, joint preclinical work, and technology transfer for manufacturing.

Oncology Infectious Focus Focus conversations on oncology and infectious disease opportunities enabled by the platform’s versatility. Potential sales angles include collaborative target discovery, co development of multispecific candidates, and vaccine applications that require multi epitope or multi antigen approaches. Offer value through translational data support, shared preclinical services, and early access to platform building capabilities.

Clinical Stage Partnerships As a clinical stage company, ModeX often needs strategic financing and parallel development routes. Position as a partner for out licensing or co development deals that fund advancement through early trials, with manufacturing readiness and regulatory strategy included in the package. Emphasize a low risk path to bring candidates into clinical testing via milestone based arrangements and joint development plans.

Massachusetts Life Sciences Based in Weston Massachusetts, ModeX sits in a dense life sciences cluster with ready access to regional CROs CMOs contract analytical services and academic collaborations. A local BD effort can target regional partners for sponsored research technology licensing and opportunistic collaborations that leverage proximity to talent and infrastructure. Propose events warm introductions and local co development programs to accelerate conversations.

Growth Oriented Partnerships With a credible revenue base and a scalable platform, ModeX is positioned for growth through strategic partnerships with mid size to large biotech players seeking an accelerated path to multispecific modalities. Target collaborations may include licensing in opportunities milestone driven co development and portfolio wide strategic investments. Identify decision makers such as the chief scientific officer head of business development and translational medicine leaders to tailor outreach and accelerate next step discussions.